Page 1 | Search Results | Blood Advances | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation

Marta Peña, Maria Queralt Salas, Alberto Mussetti, Gabriel Moreno-Gonzalez, Anna Bosch, Beatriz Patiño, Laura Jiménez, Meriem Kara, Rocío Parody, Anna Sureda

Blood Adv (2021) 5 (17): 3418–3426.

https://doi.org/10.1182/bloodadvances.2021004812

Published: 2021

Includes: Supplemental data

Journal Articles

No free rides: management of toxicities of novel immunotherapies in ALL, including financial

Tania Jain, Mark R. Litzow

Blood Adv (2018) 2 (22): 3393–3403.

https://doi.org/10.1182/bloodadvances.2018020198

Published: 2018

Journal Articles

Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide

Laura K. Schoch, Kenneth R. Cooke, Nina D. Wagner-Johnston, Ivana Gojo, Lode J. Swinnen, Philip Imus, Ephraim J. Fuchs, Mark Levis, Richard F. Ambinder, Richard J. Jones, Douglas E. Gladstone

Blood Adv (2018) 2 (17): 2226–2229.

https://doi.org/10.1182/bloodadvances.2018019208

Published: 2018

Journal Articles

The use of defibrotide in blood and marrow transplantation

Paul G. Richardson, Enric Carreras, Massimo Iacobelli, Bijan Nejadnik

Blood Adv (2018) 2 (12): 1495–1509.

https://doi.org/10.1182/bloodadvances.2017008375

Published: 2018

Journal Articles

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study

Daniel J. DeAngelo, Wendy Stock, Anthony S. Stein, Andrei Shustov, Michaela Liedtke, Charles A. Schiffer, Erik Vandendries, Katherine Liau, Revathi Ananthakrishnan, Joseph Boni, A. Douglas Laird, Luke Fostvedt, Hagop M. Kantarjian, Anjali S. Advani

Blood Adv (2017) 1 (15): 1167–1180.

https://doi.org/10.1182/bloodadvances.2016001925

Published: 2017

Includes: Supplemental data

NARROW

Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation

No free rides: management of toxicities of novel immunotherapies in ALL, including financial

Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide

The use of defibrotide in blood and marrow transplantation

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study

Email alerts

ASH Publications

American Society of Hematology

Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation

No free rides: management of toxicities of novel immunotherapies in ALL, including financial

Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide

The use of defibrotide in blood and marrow transplantation

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only